Bio-Rad Introduces CFX Opus Deepwell Real-Time PCR Detection System

Date: 
6/27/22
SEQuoia Express Stranded RNA Library Prep Kit

HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Real-Time PCR Detection System to support researchers in developing nucleic acid detection assays.

The CFX Opus Deepwell System is the latest addition to the Bio-Rad™ portfolio of CFX Opus Real-Time PCR instruments. With a 96-well block and the largest reaction volume available in the CFX Opus range — up to 125 µl — the CFX Opus Deepwell System offers accurate, precise, and reliable quantification to support assay development. The deeper sample wells of the CFX Opus Deepwell System are designed for workflows that require larger reaction volumes for pooling, certain sample prep procedures, or other specialized protocols such as in food and industrial testing, and human and veterinary pathogen detection. The Deepwell System can multiplex up to five targets simultaneously and supports fluorescence resonance energy transfer (FRET) applications. The CFX Opus Systems deliver uniform thermal cycling and powerful software, which can be linked to Bio-Rad's BR.io platform, providing remote setup, instrument monitoring, and cloud data management capabilities.

"We are witnessing an increasing demand for improved real-time PCR systems that offer more efficient workflows and enhanced data management and analysis," said Steven Blakely, Director for Gene Expression and Software Technology, Bio-Rad. "We're pleased to expand our portfolio of CFX Opus Detection Systems with the Deepwell format to help researchers perform experiments more efficiently and to consistently deliver robust datasets."

Please visit Bio-Rad.com/CFXOpusDeepwell to learn more about the Bio-Rad CFX Opus Deepwell System and other detection systems for in vitro diagnostics.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,900 employees worldwide. Bio-Rad had revenues of $2.9 billion in 2021. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contact:
Bio-Rad Laboratories, Inc.
Kate Smith, Director, Global Customer Engagement Marketing
520-741-5307
kate_smith@bio-rad.com

Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.